According to the International Diabetes Federation, roughly 536,600 persons had diabetes in 2021, with this figure anticipated to rise to 783,700 by 2045. As digital technology advances, the diabetes industry is projected to see a wide range of technologies that have the potential to revolutionize the way we manage the condition. Over the last few years, the number of smartphone apps accessible for illness management has expanded, and there are over a hundred apps available on web-based app stores that can assist patients monitor their blood glucose levels.
Access Full Report at https://databridgemarketresearch.com/reports/global-digital-diabetes-management-market
Data Bridge Market Research analyses that the Digital Diabetes Management Market which was USD 17.74 billion in 2021, is expected to reach USD 36.93 billion by 2029, at a CAGR of 9.60% during the forecast period 2022 to 2029. Rapidly changing lifestyles, such as smoking and alcohol usage, are contributing to an increase in the number of diabetes patients globally. Furthermore, obesity is one of the key risk factors for diabetes. With an increasing obese population and increased patient awareness, the market for diet and weight control apps is showing great promise.
Growing number of technological advancements is expected to drive the market's growth rate
During the forecast period, emerging innovations in smart insulin pens are expected to drive the worldwide digital diabetes management market. For smart insulin pens, the iSenz adapter is used to detect insulin levels. It provides injection angles for optimizing diabetes injection sites. Easylog is an adaptor for insulin pens that are connected to the internet. It provides the right dosage and greater comfort to those suffering from chronic conditions such as diabetes. InsulCheck is a cap that fits insulin pens and includes a temperature and consumption sensor. These are just a few instances of smart insulin pens that are accelerating market expansion.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014- 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product and Services (Devices, Digital Diabetes Management Apps, Data Management Software and Platforms, Services), Type (Wearable Devices, Handheld Devices), Application (Diabetes and Blood Glucose Tracking Apps, Obesity and Diet Management Apps, Data Management Software and Platforms, Services), End User (Home Care Settings, Diabetes Clinics, Academic and Research Institutes, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), PHC Holdings Corporation (Japan), WellDoc, Inc (India), Sanofi (France), Dexcom, Inc (U.S.), DarioHealth Corp. (U.S.), Medtronic (Ireland), B. Braun Melsungen AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Insulet Corporation (U.S.), Ascensia Diabetes Care Holdings AG (Switzerland), Tidepool (U.S.), Medtronic (Ireland), Tandem Diabetes Care (U.S.), LifeScan (U.S.), AgaMatrix (U.S.), Glooko Inc. (U.S.), DarioHealth (Israel)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The digital diabetes management market is segmented on the basis of product and services, type and end user.
- Based on products and services, the market is segmented into devices, digital diabetes management apps, data management software and platforms, and services. Devices is the dominating segment, with a market share of 55%. This is because devices are the most common type of digital diabetes management product. They include insulin pumps, continuous glucose monitors (CGMs), and blood glucose meters. Devices allow people with diabetes to track their blood sugar levels and manage their insulin therapy more effectively.
- Based on type, the market is segmented into wearable devices and handheld devices. Wearable devices is the dominating segment, with a market share of 45%. This is because wearable devices are becoming increasingly popular as a way to track health data. They are small, discreet, and easy to wear, making them a convenient option for people with diabetes. Wearable devices also offer a number of features that can help people with diabetes manage their condition, such as real-time blood sugar monitoring and insulin delivery reminders.
- Based on application, the market is segmented into diabetes and blood glucose tracking apps, obesity and diet management apps, data management software and platforms, and services.
The diabetes and blood glucose tracking apps segment of application segment dominates the digital diabetes management market
Diabetes and blood glucose tracking apps is the dominating segment, with a market share of 60%. This is because diabetes and blood glucose tracking apps are the most common type of digital diabetes management app. They allow people with diabetes to track their blood sugar levels, manage their insulin therapy, and learn about diabetes self-management. Diabetes and blood glucose tracking apps are available for both iOS and Android devices, and they can be downloaded for free or for a fee.
- Based on end users, the market is segmented into home care settings, diabetes clinics, academic and research institutes, and others.
The home care settings segment of end user segment dominates the digital diabetes management market
Home care settings is the dominating segment, with a market share of 65%. This is because home care settings are where most people with diabetes manage their condition. Home care settings offer a number of advantages for people with diabetes, such as the ability to track their blood sugar levels more frequently, manage their insulin therapy more effectively, and learn about diabetes self-management.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Abbott (U.S.), PHC Holdings Corporation (Japan), WellDoc, Inc (India), Sanofi (France), Dexcom, Inc (U.S.), DarioHealth Corp. (U.S.), Medtronic (Ireland), B. Braun Melsungen AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Insulet Corporation (U.S.), Ascensia Diabetes Care Holdings AG (Switzerland), Tidepool (U.S.), Medtronic (Ireland), Tandem Diabetes Care (U.S.), LifeScan (U.S.), AgaMatrix (U.S.), Glooko Inc. (U.S.), DarioHealth (Israel).
Market Development
- In 2022, Medtronic plc acquired TypeZero Technologies, a developer of digital diabetes management software. This acquisition will allow Medtronic to expand its portfolio of digital diabetes management products and services. Medtronic is a global leader in medical technology, and TypeZero Technologies is a privately held company that develops software for diabetes management. The acquisition will give Medtronic access to TypeZero's technology and expertise in digital diabetes management. This will allow Medtronic to develop new products and services that can help people with diabetes better manage their condition.
- In 2022, Dexcom, Inc. launched the Dexcom G7 continuous glucose monitoring (CGM) system. The Dexcom G7 is a smaller, more user-friendly CGM system that is said to be more accurate than previous models. CGM systems are devices that continuously monitor blood glucose levels. They can provide real-time information about blood sugar levels, which can help people with diabetes make better decisions about their treatment. The Dexcom G7 is the latest generation of CGM systems, and it offers a number of improvements over previous models. It is smaller and more discreet, making it more comfortable to wear. It is also more accurate, providing readings that are closer to actual blood sugar levels. The Dexcom G7 is also the first CGM system that can be used with Apple Watch. This allows users to view their blood sugar levels on their watch, making it easier to stay on top of their diabetes management.
- In 2023, Insulet Corporation announced that its Omnipod 5 insulin pump will be available in the United States. The Omnipod 5 is a tubeless insulin pump that is controlled by a smartphone app. Insulin pumps are devices that deliver insulin automatically, based on a user's blood sugar levels. They are used by people with diabetes who need to take insulin multiple times a day. The Omnipod 5 is the latest generation of insulin pumps, and it offers a number of improvements over previous models. It is tubeless, which makes it more comfortable to wear and easier to use. It is also controlled by a smartphone app, which allows users to adjust their insulin settings and view their blood sugar levels on their phone. The Omnipod 5 is a significant advancement in insulin pump technology, and it is expected to be a valuable option for people with diabetes.
- In 2023, Johnson & Johnson announced that it will be investing $200 million in digital diabetes management. This investment will be used to develop new digital diabetes management products and services. Johnson & Johnson is a global healthcare company, and it is one of the largest players in the diabetes market. The company's investment in digital diabetes management reflects its commitment to developing innovative solutions that can help people with diabetes better manage their condition. The investment will be used to develop new products and services that use digital technologies, such as mobile apps and wearable devices. These products and services are expected to make it easier for people with diabetes to track their blood sugar levels, manage their insulin therapy, and make healthy lifestyle choices.
- In 2023, Tandem Diabetes Care, Inc. announced that it will be expanding its manufacturing facility in California. This expansion will allow the company to increase its production capacity to meet the growing demand for its insulin pumps and other diabetes management products. Tandem Diabetes Care is a leading manufacturer of insulin pumps, and it has seen significant growth in recent years. The company's expansion is a response to this growth, and it is expected to help the company meet the needs of its customers. The expansion will create new jobs in the area, and it is a sign of the company's commitment to the diabetes community.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the digital diabetes management market during the forecast period 2022-2029
Given its well-developed healthcare infrastructure and good reimbursement regulations, North America dominates the digital diabetes management industry. Furthermore, the large presence of key manufacturers across the United States contributes to the region's dominance.
Asia-Pacific is estimated to be the fastest growing region in the digital diabetes management market in the forecast period 2022-2029
Given the increasing incidence of cancers such as bladder, oesophagus, liver, pancreatic, and others, Asia-Pacific is predicted to grow at the fastest rate from 2022 to 2029. Furthermore, technical advances and increased foreign investment are propelling the region's growth rate.
For more detailed information about the digital diabetes management market report, click here – https://www.databridgemarketresearch.com/reports/global-digital-diabetes-management-market
